Pharming Group NV · EURONEXT:PHARM
Pharming Group NV — H1 2018 Earnings Presentation
22 slides from Pharming Group NV's earnings presentation, Jul 26, 2018
Slide 1: Pharming Group NV Half Year Results 2018
Pharming Group NV Half Year Results 2018 Sijmen de Vries Chief Executive Officer Robin Wright Chief Financial officer 26 July 2018 1
Slide 2: Safe harbour statement
Safe harbour statement The information contained in this document and communicated verbally to you (together the "Presentation") is being supplied to you solely for your information and may not be copied, reproduced or further distributed to any person or published, in whole or in part, for any purp
Slide 3: Half year results 2018
Half year results 2018 % Pharming
Slide 4: Operational highlights
Operational highlights • Continued underlying growth for RUCONEST® in the USA following stabilisation of short supply situations at major competitors, driving growth and good patient retention rates • FDA acceptance of sBLA file for RUCONEST® for prophylaxis of HAE, with an action date set for 21 Se
Slide 5: Continued growth in US sales
Continued growth in US sales # of Patients Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Data to 30 June 2018 5
Slide 6: Financial highlights
Financial highlights • Delivered net profitability for the half year • Revenues from product sales for the half year increased by 96% to €59.1 million (HY 2017: €30.1 million), as a result of the continued increasing patient numbers • Operating results improved by 288% to a profit of €16.3 million f
Slide 7: Investing for Long-term Growth
Investing for Long-term Growth 7
Slide 8: The HAE market
The HAE market • All current and known future prophylaxis therapies continue to have limitation of use as result of their specific efficacy and safety characteristics • In addition, supply constraints and limited up-scalability of plasma-derived C1 inhibitor manufacturing have been and are expected
Slide 9: Label expansion and improving patient convenience
Label expansion and improving patient convenience New label extensions for recombinant C1 esterase inhibitor (RUCONEST®) • Prophylaxis of HAE attacks (under FDA review, with action date 21 September) • Treatment of young HAE patients (pediatric label, under review after positive opinion) New routes
Slide 10: New indications to drive long-term value
New indications to drive long-term value New large indications for recombinant C1 esterase inhibitor (RUCONEST®) • Contrast-induced nephropathy (“CIN” : large life-threatening indication with ~1 million patients, no approved therapy) • Potentially cardiac protection (very large new indication – depe
Slide 11: Significant potential addressable future markets
Significant potential addressable future markets Patient numbers 10 million Cardiac protection Hypovolemic Shock 1 million Contrast- Induced Nephropathy Pre-Eclampsia 100,000 Fabry’s DGF Pompe 10,000 HAE Potential for Revenues Not to scale! 11
Slide 12: Expansion of Pharming to a wide market, multiple product franchise
Expansion of Pharming to a wide market, multiple product franchise Lead Preclinical Phase I Phase II Phase III Approval & Optimization Commercialization RUCONEST® Acute Hereditary Angioedema (HAE) RUCONEST® HAE Prophylaxis (IV) HAE Prophylaxis (SC and ID) HAE-related RUCONEST® RUCONEST® HAE Acute (I
Slide 13: Potential for significant clinical newsflow over the coming years
Potential for significant clinical newsflow over the coming years Assumed solely for purpose of diagram: positive results of studies 2018 2019 2020 Phase II Phase III Ruconest SC, IM, ID Ruconest SC, IM, ID PDUFA HAE Prophylaxis IIS in CIN Phase II CIN Phase III CIN Phase II Cardiac Protection Phase
Slide 14: Financial information & statements
Financial information & statements 14
Slide 15: Income statement
Income statement Amounts in €’000 HY 2018 HY 2017 Product sales 59,051 30,109 License fees 403 536 Revenues 59,454 30,645 Costs of sales (9,473) (3,657) Gross profit 49,981 26,988 Other income 300 167 Research and development (12,013) (9,154) General and administrative (5,242) (2,628) Marketing and
Slide 16: Balance sheet - Assets
Balance sheet - Assets Amounts in €’000 Notes 30 June 31 December 2018 2017 Intangible assets 55,843 56,631 Property, plant and equipment 8,291 8,234 Long term prepayment 1,865 2,296 Deferred tax asset 8,526 9,442 Restricted cash 1,366 1,336 Non-current assets 75,891 77,939 Inventories 9 23,162 18,3
Slide 17: Balance Sheet - Liabilities
Balance Sheet - Liabilities Amounts in €’000 Notes 30 June 31 December 2018 2017 Share capital 6,104 5,790 Share premium 387,760 370,220 Legal reserves (1,098) (938) Accumulated deficit (352,101) (356,270) Shareholders’ equity 10 40,665 18,802 Loans and borrowings 11 47,860 58,684 Deferred license f
Slide 18: Cash flow - Operating Activities
Cash flow - Operating Activities Amounts in €’000 HY 2018 HY 2017 Operating result 16,290 4,233 Non-cash adjustments: Depreciation, amortization 1,903 1,689 Accrued employee benefits 1,750 872 Deferred license fees (403) (536) Operating cash flows before changes in working capital 19,540 6,258 Chang
Slide 19: Cash flow - Overall
Cash flow - Overall Amounts in €’000 HY 2018 HY 2017 Net cash flows generated from (used in) operating activities 9,566 (4,190) Capital expenditure for property, plant and equipment (1,380) (1,457) Investment intangible assets (634) (598) Net cash flows used in investing activities (2,014) (2,055) P
Slide 20: Outlook 2018
Outlook 2018 2 % Pharming
Slide 21: Outlook for 2018
Outlook for 2018 For the remainder of 2018, the Company expects: • Continued growth in revenues from sales of RUCONEST®, mainly driven by the US operations • Achievement of additional positive quarterly (operating and net) results throughout the remainder of the year • Continued investment in the pr
Slide 22: Tickers: ENXTAM: PHARM Bloomberg: PHAR.AS
Tickers: ENXTAM: PHARM Bloomberg: PHAR.AS 22